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Abstract
b-Sheet-rich aggregates of a-synuclein (aSyn) are the hallmark neuropathology of Parkinson’s disease and related
synucleinopathies, whereas the principal native structure of aSyn in healthy cells - unfolded monomer or a-helically folded
oligomer - is under debate. Our recent crosslinking analysis of aSyn in intact cells showed that a large portion of
endogenous aSyn can be trapped as oligomers, most notably as apparent tetramers. One challenge in such studies is
accurately quantifying aSyn Western blot signals among samples, as crosslinked aSyn trends toward increased
immunoreactivity. Here, we analyzed this phenomenon in detail and found that treatment with the reducible amine-
reactive crosslinker DSP strongly increased aSyn immunoreactivity even after cleavage with the reducing agent b-
mercaptoethanol. The effect was observed with all aSyn antibodies tested and in all sample types from human brain
homogenates to untransfected neuroblastoma cells, permitting easy detection of endogenous aSyn in the latter, which had
long been considered impossible. Coomassie staining of blots before and after several hours of washing revealed complete
retention of aSyn after DSP/b-mercaptoethanol treatment, in contrast to a marked loss of aSyn without this treatment. The
treatment also enhanced immunodetection of the homologs b- and c-synuclein and of histones, another group of small,
lysine-rich proteins. We conclude that by neutralizing positive charges and increasing protein hydrophobicity, amine
crosslinker treatment promotes adhesion of aSyn to blotting membranes. These data help explain the recent report of fixing
aSyn blots with paraformaldehyde after transfer, which we find produces similar but weaker effects. DSP/b-
mercaptoethanol treatment of Western blots should be particularly useful to quantify low-abundance aSyn forms such
as extracellular and post-translationally modified aSyn and splice variants.
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Introduction
The synuclein family consists of a-, b- and c-Synuclein (aSyn,
bSyn, cSyn), small soluble proteins with a molecular weight below
15 kDa. aSyn is by far the best known and most studied among
the three, due to its strong link with Parkinson’s disease (PD), the
second most common human neurodegenerative disease. Point
mutations and copy number variants in the aSyn gene cause
familial forms of PD [1–4], and aSyn is the major component of
Lewy bodies, intraneuronal protein aggregates that are the
cytopathological hallmark of both familial and sporadic PD [5].
Its central role in PD pathogenesis has attracted considerable
research into the biochemical, biophysical and functional proper-
ties of aSyn. However, despite more than two decades of aSyn
research, essential features, such as molecular function, interaction
partners, structure, and even sub-cellular localization, are still
contentious. Recent developments indicate that results of studies of
aSyn are dependent on the model system used: standard
recombinant expression of aSyn in bacteria, for example, provides
large quantities of protein suitable for biophysical and structural
analyses, but this protein may insufficiently replicate the
posttranslational modifications, folding and oligomerization of
the endogenous protein in neurons [6–10]. Analysis of aSyn in
eukaryotic cells, on the other hand, is limited by relatively low
abundance and various technical challenges. For example,
Western blot analysis of endogenous aSyn in immortalized cell
lines, even those of neuronal origin such as SH-SY5Y, had long
been considered almost impossible due to extremely low expres-
sion levels [11]. A recent publication, however, has challenged this
view by demonstrating that clear and strong detection of total
endogenous aSyn from cultured cells is facilitated by fixation of
proteins on blotted membranes with low concentrations of
paraformaldehyde (PFA) [12], a method previously applied to
the study of hemoglobin [13]. The authors suggest that this
treatment prevents washing off of synuclein from PVDF or
nitrocellulose membranes. We applied their method in a previous
study of aSyn crosslinking, and it enabled meaningful Western blot
comparisons of monomeric and oligomeric aSyn species without
vs. with crosslinking [12]. Here, we report that immunodection of
aSyn monomer can be improved even further – by more than
100% – with the application of reducible amine-reactive cross-
linkers such as dithiobis[succinimidylpropionate] (DSP) followed
by reductive cleavage (5% bME), prior to SDS-PAGE and
electroblotting. In a variety of samples from neuroblastoma cell
lines to human brain, we demonstrate that our novel method of
improved aSyn monomer immunodetection is superior to the PFA
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PVDF membranes and stained with Coomassie dye before and
after hours of washing was virtually 100% retained on the
membrane with DSP/bME treatment, while untreated aSyn was
nearly completely lost. Moreover, we observed the same
enhancement of monomer immunodetection with the synuclein
homologs b- and cSyn, as well as with another group of small,
lysine-rich proteins, the histone family, suggesting that this new
method may also benefit work outside the field of aSyn research.
Materials and Methods
Cell culture
All materials were purchased from Invitrogen unless stated
otherwise. All cells were cultured at 37uC in a 5% CO2
atmosphere. Human erythroid leukemia cells (HEL; ATCC
number TIB-180) were cultured in RPMI 1640 (ATCC modifi-
cation) supplemented with 10% fetal bovine serum (Sigma),
10 units/mL penicillin and 10 mg/mL streptomycin (Pen-Strep).
Human neuroblastoma cells BE(2)-M17 (called M17D; ATCC
number CRL-2267) and 3D5, an M17D-derived line overexpress-
ing wild type human aSyn regulated by the tetracycline-off system
[14], were cultured in high-glucose DMEM supplemented with
10% FBS, 2 mM L-glutamine and Pen-Strep. Doxycycline was
added to cell medium to a final concentration of 100 ng/mL to
repress aSyn expression. The human neuroblastoma cell line SH-
SY5Y (ATCC number CRL-2266) was cultured in a 1:1 mixture
of high-glucose DMEM and F-12 supplemented with 10% FBS,
2 mM L-glutamine and Pen-Strep.
Sample preparation from cultured cells and brain tissues
Our method of generation of cytosolic lysates from cultured
human cell lines and primary rat neurons has been described [7].
In this study, membranes were routinely pelleted by centrifugation
at 100,000 g for 60 min at 4uC. Brain homogenates from frozen
mouse brain and human brain were generated by thawing, dounce
homogenization and 15 s sonication (Sonic Dismembrator model
300, Fisher Scientific, Waltham, MA; microtip setting = 40).
Brains were dissected from C57BL/6 male mice aged 11–13 weeks
(Jackson Laboratory, Bar Harbor, ME) and stored at –80uC. A
sample of human cerebral cortex from a neurologically normal
subject was stored at –80uC.
Ethics Statement
The use of human brain samples was approved under protocol
number 1999P001180 (’Aging in the Brain: Role of the Fibrous
Proteins’) by the Partners Human Research Committee (PHRC),
the Institutional Review Board (IRB) of Partners Research
Management. Informed written consent for the use of post-
mortem brain tissue was obtained from the families donating the
patients’ brains to research when they enrolled in our CND Tissue
Donation Program. The neuropathologist obtained consent at the
time of autopsy. Rodent samples were acquired under protocol
number 05022 (’Mouse Models for Parkinson’s Disease’), ap-
proved by the appropriate IACUC, the Harvard Medical Area
Standing Committee on Animals.
Crosslinkers
Dithiobis[propionimidate] (DTBP), dithiobis[succinimidylpro-
pionate] (DSP) and disuccinimidylglutarate (DSG) were from
Pierce. Crosslinkers were dissolved in DMSO to a 50X stock
concentration prior to addition to sample. Detailed crosslinking
protocols (in vivo and in vitro with cells and on recombinant protein)
are in [7].
Electrophoresis & Immunoblotting
All materials were purchased from Invitrogen unless stated
otherwise. Total protein concentrations were determined by BCA
assay (Thermo Scientific) according to manufacturer’s directions.
Samples were prepared for electrophoresis by diluting with 4X
NuPAGE sample buffer with or without 20% b-mercaptoethanol
followed by boiling for 10 min. Routinely, 15–30 mg of sample
were electrophoresed on NuPAGE 4–12% Bis-Tris gels with
NuPAGE MES-SDS running buffer and the SeeBlue Plus2
molecular weight markers. After electrophoresis, gels were blotted
onto Immobilon-PSQ 0.2-mm PVDF (Millipore) for 90 min at
400 mA constant current at 4uC in 25 mM Tris, 192 mM glycine,
20% methanol transfer buffer. Unless stated otherwise, post-
transfer membranes were treated with 0.4% paraformaldehyde
(PFA) in PBS for 30 min at RT and then rinsed with water [12].
Blocking was in 0.2% iBlock (Applied Biosystems) in PBS with
0.1% (v/v) Tween-20 (PBST) for $30 min. Membranes were then
incubated in primary antibody in 0.2% iBlock in PBST with
0.02% sodium azide for either 1 h at RT or overnight at 4uC.
Membranes were then washed 3610 min in PBST and incubated
in secondary antibody in 0.2% iBlock in PBST followed by
washing 3610 min in PBST and developing with ECL Prime (GE
Healthcare-Amersham Biosciences) according to the manufactur-
er’s instructions. To visualize proteins on PVDF, membranes were
briefly incubated in Ponceau solution or Coomassie (PageBlue
Protein Staining Solution, Thermo Scientific; application on dried
membranes).
Antibodies
2F12, a monoclonal antibody (mAb) to aSyn, was produced in-
house [7]. Other aSyn mAbs were 15G7 [15] and Syn1 (Clone 42,
Becton-Dickinson), and polyclonal antibody (pAb) C20 (Santa
Cruz) was also used. Other antibodies were mAb EP1537Y to b-
synuclein (Novus Biologicals), pAb 6169 to c-synuclein (Abcam),
mAb 8226 to b-actin (Abcam), mAb AA2 to b-tubulin (Sigma),
mAb to calmodulin (05-173, Millipore), mAb 71.1 to GAPDH
(Sigma), pAb to DJ-1 ([16]), pAb to RAN (4462, Cell Signaling),
pAb to 14-3-3 (9063, Abcam), pAb to UCH-L1 (ab1761,
Millipore), pAb to Histone H3 (9715, Cell Signaling), and pAb
to trimethyl Histone H3 Lys27 (ABE44, EMD Millipore).
Semiquantitave densitometry of Western blot signals
Scanned Western blots were analyzed with ImageJ software,
version 1.47 [17]. Pictures were inverted and background signal
from an empty lane subtracted to obtain the actual signals for each
lane.
Results
Discrepancy between immunoblotting of aSyn from
crosslinker-treated and untreated lysates
We recently published a detailed crosslinking analysis of aSyn in
intact cells [7] that led us to conclude that a large portion of
endogenous cytosolic aSyn exists in physiological oligomers,
principally apparent tetramers, consistent with previous studies
from our lab [6] and others [8–10]. In contrast to these findings,
some labs have recently published evidence that leads them to
support the earlier model that physiological aSyn exists in cells and
tissues principally as unfolded monomers. However, these studies
either did not include the intact-cell crosslinking approach [18], or
the trapping of aSyn at oligomeric (e.g., dimeric) positions by
crosslinking was considered unspecific [19]. One challenge in
studying aSyn by crosslinking is achieving equality of Western blot
signals between crosslinker- and control-treated samples. In most
Quantitative Immunoblotting of a-Synuclein
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somewhat greater immunoreactivity than did non-crosslinked
aSyn [7]. We speculated that unmodified aSyn may be washed off
of Western blot membranes, whereas crosslinker modification
might prevent this loss. This hypothesis emerged from the finding
of Lee and Kamitani that 0.4% paraformaldehyde (PFA) fixing of
blot membranes prevented the apparent loss of aSyn monomers
during immunoblotting, thereby enhancing their immunodetec-
tion [12]. By including their PFA step in our standard protocol for
aSyn crosslinking analysis, we achieved quantitatively meaningful
results (‘conservation of aSyn immunochemical matter’) to a much
greater extent: the combined immunoreactivity of all aSyn species
after crosslinking roughly approximated that of the monomer
alone before crosslinking. However, even with the routine use of
PFA treatment, we still found some inconsistencies in the relative
aSyn immunoreactivities of untreated and crosslinker-treated
samples. For example, we observed certain trends in aSyn
immunodetection, as exemplified by primary rat neurons (Fig.
1a, two left panels are short and long exposures). First, treatment
of intact neurons with increasing amounts of the reducible amine
crosslinker DSP resulted in a stepwise increase in aSyn monomer
immunoreactivity (lanes 2 and 3) compared to the vehicle (DMSO)
treated control (lane 1), until at a higher DSP concentration, aS-60
(aSyn tetramer) was trapped (lane 4). Second, low amounts of the
non-reducible amine crosslinker DSG trapped small amounts of
aSyn oligomers but still increased monomer detection (lane 6)
compared to DMSO alone (lane 1). Third, a higher DSG
concentration trapped more oligomeric aSyn (lane 7), but this
increase was not accompanied by a corresponding decrease in
detected monomer compared to DMSO alone (lane 1). Fourth, an
even higher DSG concentration led to appearance of a high MW
aSyn-reactive smear, primarily at the expense of the monomer
signal (lane 8). Densitometry of these blots (Fig. 1b, left and middle
panel) supported these qualitative impressions and suggested that
the relative immunoreactivity of the crosslinker-treated and
untreated samples that one observes depends on the exposure
time of the blot. Most importantly, longer blot exposures reveal the
presence of HMW smears at higher DSG concentrations, thus
exaggerating the total aSyn immunoreactivity in those lanes (see
lane 8). A parallel analysis for the well-known dimeric protein DJ-1
revealed better conservation of total immunoreactivity between
the treatments for this control protein and no appearance of high
MW smears (Western blot: Fig. 1a, right panel; densitometry: Fig.
1b, right panel).
Lysine modification increases aSyn immunoreactivity by
strengthening attachment to blot membranes
As Western blotting is only a semi-quantitative method, given
the potential for signal saturation and overestimation of diffuse
immunoreactivity, the increase in total aSyn immunoreactivity in
the crosslinked samples was not unexpected, particularly in those
with larger amounts of trapped oligomers and upon long exposure
times. Nevertheless, the increase in aSyn monomer signal at
crosslinker amounts that trapped only trace amounts of aSyn
oligomers (Fig. 1a, lanes 2, 3 and 6) was unanticipated. This
phenomenon was reminiscent of our difficulty in achieving
equality of Western blot signals between crosslinker- and
control-treated samples when initially blotting for aSyn without
PFA treatment. We therefore reasoned that Western blotting
preferentially detects crosslinker-modified aSyn, whether mono-
meric or oligomeric, even when PFA fixation is used. We
hypothesized that PFA treatment of blots alone does not fully
prevent aSyn from washing off during development, whereas
robust crosslinker-modification of the lysine residues in the protein
may be sufficient. To test this, we treated human erythroid
leukemia (HEL) cells (which express high endogenous levels of
aSyn [7]) with 1 mM of DSP in vivo or DMSO only, then
generated high-speed cytosols, normalized for protein concentra-
tion, and cleaved the reducible crosslinker by adding 5% bME
before samples were boiled for SDS-PAGE. By Western blot
analysis on PFA treated blots, we observed a markedly enhanced
signal for aSyn in the DSP/bME-treated sample (Fig. 2a, right
panel). Importantly the control protein DJ-1 did not show a similar
effect (Fig. 2a, middle panel), and Ponceau staining of the PVDF
membrane did not indicate higher protein loading in the DSP/
bME lane (left panel). We then tested our paradigm on the
primary neurons and found that in addition to in vivo (not shown)
even in vitro DSP treatment (addition of DSP to cytosolic lysates)
followed by bME cleavage enhanced the aSyn immunosignal (Fig.
2b, second panel from the left, compare left and right lanes). Signal
for the control monomeric protein b-tubulin (Fig. 2b, right panel,
upper part) was not affected by DSP treatment, but bSyn and
cSyn (Fig. 2b, third panel from the left and right panel, bottom
part) showed similar marked enhancement of monomer by DSP/
bME as did aSyn. Ponceau staining (Fig. 2b, left panel) and
blotting for b-tubulin (Fig. 2b, right panel, top part) ruled out
higher protein loading in the DSP/bME lanes, as expected.
Our next step was to test the DSP/bME treatment on the aSyn
protein source most relevant to the study of Parkinson’s disease,
human brain (Fig. 2c, left two lanes labled ‘H.s.’). Again, we
observed a strong signal enhancement for aSyn monomers with
DSP/bME treatment of brain homogenates (Fig. 2c, lowest panel).
A similar effect was achieved with mouse brain homogenates (Fig.
2c, right two lanes labled ‘M.m.’). The control proteins b-tubulin
and b-actin behaved differently, as their signals were unaffected (b-
tubulin) or decreased (b-actin) by DSP/bME treatment. Based on
the PFA result of Lee and Kamitani [12], we had initially
hypothesized that increased immunodetection of aSyn by
improved blotting procedures was a result of the aSyn protein
not washing off the blot. However, alternate explanations such as
enhanced antibody accessibility to aSyn were possible although
unlikely, as all aSyn antibodies tested so far led to similar results.
To rule out this possibility by avoiding the need for immunodetec-
tion, we turned to pure aSyn protein. Purified recombinant aSyn
[20] and purified hen-egg lysozyme as a control [7] were
incubated with DSP/bME or DMSO alone (Fig. 2d). All four
conditions (two proteins, each with two treatments) were subjected
to SDS-PAGE followed by transfer to a PVDF membrane. One
part of the membrane (containing all four samples) was dried
immediately after transfer, reducing the risk of subsequent protein
wash-off (Fig. 2d, left panel). The other half of the membrane (also
containing all 4 samples) was incubated overnight in our standard
wash buffer (PBS with 0.1% Tween-20; PBST), then briefly
washed in water and dried as well (Fig. 2d, right panel). We
visualized the proteins on the dried membranes by brief
incubation in Coomassie (see Materials and Methods), which we
identified as the best method because it stained untreated and
DSP/bME-treated aSyn similarly well. (Ponceau staining under-
estimated protein in crosslinker-treated samples, as it binds to
positive charges, which are neutralized by the crosslinker; see Fig.
2a.). We found that unmodified aSyn, while fully present
immediately after transfer (Fig. 2d, left half), was almost entirely
gone after overnight washing of the blot (right half). In striking
contrast, DSP/bME-treated aSyn was detectable to a similar
extent with and without overnight washing. The control protein,
lysozyme, was largely unaffected by any of the conditions. We
conclude that the enhancing effect of DSP/bME on aSyn
immunodetection is indeed a result of less washing-off of the
Quantitative Immunoblotting of a-Synuclein
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over, the Coomassie staining in Fig. 2d shows that the DSP/bME
method quantitatively retains aSyn on the membrane.
In vitro incubation of lysates with 2 mM DSP followed by
bME reduction allows optimal aSyn detection
To optimize the DSP/bME method, we focused on human
erythroid leukemia (HEL) cells, which are rich in endogenous
aSyn, more consistent, and more readily available than primary
neurons or brain samples [7]. We compared the cleavable
crosslinkers DSP (spacer length 12.0 A ˚) and dithiobis[propionimi-
date] (DTBP, spacer length 11.9 A ˚) (Fig. 3a). We tested
concentration gradients of 0.5, 2.0 and 8.0 mM of each crosslinker
vs. DMSO alone (-) and both in vivo and in vitro. DTBP/bME
treatment had a similar but weaker effect as DSP/bME, and DSP
concentrations higher than 2 mM had no additional benefit,
suggesting saturation of the mechanism. Overall, we observed
no major differences between the in vivo and in vitro treatments
Figure 1. Discrepancy between immunoblotting of aSyn from crosslinker-treated and untreated lysates. A. Intact primary cortical rat
neurons (13 days in vitro) were incubated with DMSO only (-) or a gradient of 0.1, 0.5 and 1.0 mM DSP or DSG, sonicated in PBS supplemented with
protease inhibitors and spun at 100,000 g for 60 min. The resultant cytosols (30 mg) were blotted with aSyn antibody Syn1 (left panel: short exposure;
middle panel: long exposure) and with anti-DJ-1 as a control (right panel). Arrows indicate the crosslinker-trapped aSyn species that have been
described before [7] as well as the DJ-1 dimer (2-mer) and monomer (1-mer). B. Densitometric analysis of the blots shown in Fig. 1a using ImageJ (see
Materials and Methods). Bars indicate the total immunoreactivity of each lane as a percentage of the signal from DMSO-only treated sample (lane 1),
after subtraction of the background from the empty lane 5.
doi:10.1371/journal.pone.0081314.g001
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intact cells, we focused on the in vitro approach for further method
optimization and on the more efficient compound, DSP. We
checked whether the protein concentration during in vitro cross-
linking affected the degree of aSyn detection on Western blots
(Fig. 3b) and saw no clear trend with lysate protein concentrations
of 2.4, 3.3 and 4.5 mg/mL for the two aSyn antibodies we tested,
2F12 and 15G7, using a DSP gradient paradigm analogous to
Fig. 3a. Independent of the lysate protein concentration, we found
a strong enhancement of aSyn immunodetection by DSP/bME
treatment that plateaued at 2 mM DSP, while immunodetection
of GAPDH was unaffected. However, we subsequently chose a
cytosol protein concentration range of between 2 and 5 mg/mL for
in vitro treatments. We next confirmed the strong aSyn enhance-
ment by DSP/bME using two more aSyn antibodies, C20 and
Syn1, while the signals of several control proteins were more
Figure 2. Lysine modification increases aSyn immunoreactivity by strengthening attachment to blot membranes. A. HEL cells were
crosslinked in vivo with the cleavable crosslinker DSP (1 mM) in comparison to DMSO-only treatment (-). Cytosols were prepared (post-20,000 g) and
boiled in sample buffer with 5% (v/v) b-mercaptoethanol (bME), which cleaves the disulfide bond of DSP (DSPßME: reduced DSP). Samples (30 mg)
were blotted with aSyn antibody 15G7. Equal protein loading was visualized by blotting for DJ-1 and by Ponceau (Ponc.) staining. B. Primary cortical
rat neurons (13 days in vitro) were treated with 1 mM DSP in vitro (cytosolic lysates) in comparison to DMSO-only (-) treatment. Cytosols (post
100,000 g) were boiled in sample buffer with 5% bME and blotted with aSyn antibody 2F12, as well as antibodies to bSyn, cSyn and b-tubulin (b-tub.).
Ponceau (Ponc.) stain of the blot membrane is shown on the left. C. Human (H.s.; 15 mg) and mouse (M.m., 30 mg) brain homogenates (PBS soluble
fraction; post 100,000 g) were treated in vitro with DSP or DMSO-only (-), followed by boiling in sample buffer containing 5% bME. Blots were
developed with aSyn antibody Syn1 as well as antibodies to b-tubulin, b-actin, GAPDH and DJ-1. D. Purified recombinant aSyn and purified hen-egg
lysozyme (lyz) were crosslinked at a concentration of 500 ng/mL with 2 mM DSP (DSPßME) in comparison to DMSO only (-), followed by boiling in
sample buffer with 5% bME. After separation by SDS-PAGE, samples were transferred to PVDF membranes which were dried immediately (left panel:
‘no wash’) or after washing overnight in PBST (‘wash’). Dried membranes were briefly stained with Coomassie Blue. 14, 17 and 28 kDa molecular
weight markers are visible in the outer left lane.
doi:10.1371/journal.pone.0081314.g002
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b-actin) (Fig. 3c). All samples shown in Fig. 3 were treated with
bME at 5% final concentration, ruling out the possibility that the
reducing agent alone is responsible for the increased immunode-
tection. This was confirmed when we boiled untreated lysates in
the presence or absence of bME and subsequently blotted for aSyn
(not shown).
DSP/bME treatment allows facile detection of aSyn from
cultured cells
Finally, we tested how well our method detects aSyn in readily
available sources whose aSyn expression levels have previously
been underestimated, such as cultured cell lines of neuronal origin.
We compared the levels of aSyn immunoblot detection with vs.
without DSP/bME treatment in the tet-off aSyn overexpressing
line 3D5 [14], in the absence (Fig. 4a, top two panels, lanes 1 and
2) and presence (lanes 3 and 4) of doxycycline, to their parental cell
line M17D expressing only endogenous aSyn (lanes 6 and 7).
Western blotting confirmed very strong expression in induced 3D5
cells compared to doxycycline-repressed 3D5 cells, which still
expressed more aSyn than the parental M17D line due to
incomplete repression. We observed the aSyn signal-enhancing
effect of DSP/bME treatment independently of expression level
(compare ‘-‘ lanes to ‘+’ lanes). Detection of the control protein DJ-
1 also benefited from DSP/bME treatment to some degree in this
experiment, while b-actin detection was again reduced somewhat.
Consistent with the report of Lee and Kamitani, PFA treatment
alone of the PVDF membranes after transfer already improved
detection of endogenous aSyn from these neuroblastoma cells.
Nevertheless, additional incubation of the lysates with DSP/bME
further enhanced the aSyn signal markedly. We obtained similar
results for another commonly studied neuroblastoma cell line, SH-
SY5Y (Fig. 4b, lanes 3 and 4). The relative levels of aSyn detected
in M17D and SH-SY5Y cells and in human brain homogenates
was not changed by DSP/bME treatments, i.e., the aSyn signals
were proportionally enhanced regardless of aSyn abundance in
the respective source (Fig. 4b, compare long blot exposure for
neuroblastoma cells to short exposure for human brains).
To compare systematically the effects of DSP/bME treatment
of protein lysates and PFA treatment of blot membranes, we
analyzed DSP/bME- and vehicle-treated lysates of SH-SY5Y cells
(Fig. 4c) and M17D cells (Fig. 4d) on PVDF membranes with and
without PFA treatment. All four aSyn antibodies used routinely in
our lab (2F12, 15G7, Syn1, C20) showed the aSyn-enhancing
effect of PFA in both cell lines (Figs. 4c and 4d, compare lane 1 to
lane 3 in all aSyn panels). DSP/bME treatment, however, led to
substantial additional aSyn signal on PFA-treated membranes
(Figs. 4c and 4d, compare lane 3 to lane 4 in all aSyn panels). In
fact, the strong aSyn signals caused by DSP/bME treatment of the
lysates were not significantly enhanced further by additional PFA
treatment of the blots (Figs. 4c and 4d, compare lane 2 to lane 4 in
all aSyn panels), suggesting that the two treatments do not have
additive effects. Furthermore, we tested these same samples on
multiple types of transfer membrane – 0.2 mm pore PVDF (our
standard), 0.45 mm pore PVDF and 0.2 mm pore nitrocellulose –
and found no differences among these membrane materials (data
not shown). While signals for most control proteins were either
unchanged (UCH-L1, b-tubulin) or reduced (GAPDH) by DSP/
bME treatment, we did observe an immunodetection enhancing
effect on the histone protein H3 using an antibody to total H3 as
Figure 3. In vitro incubation of lysates with 2 mM DSP followed by bME reduction allows optimal aSyn detection. A. HEL intact cells (in
vivo) or lysates (in vitro) were incubated with DMSO only (-) as well as gradients of 0.5, 2.0 and 8.0 mM DSP and DTBP, respectively. Cytosols (post-
100,000 g) were boiled in sample buffer/5% bME and blotted with aSyn antibody 2F12. Identical exposures of the same blot are shown; film was cut
at dotted line. B. HEL cell cytosols (post-100,000 g) at three different protein concentrations (2.4, 3.3., 4.5 mg/mL) were incubated with DMSO only (-)
as well as a gradient of 0.5, 2.0 and 8.0 mM DSP and DSG. Samples were normalized to 2.4 mg after quenching, then boiled in sample buffer plus 5%
bME and blotted with aSyn antibodies Syn1 and 15G7 as well as an antibody to GAPDH. C. HEL cell cytosols (post-100,000 g) were treated with
DMSO-only (-) or DSP, quenched, boiled in sample buffer plus 5% bME and analyzed by blotting for aSyn (mAb Syn1 and pAb C20), Calmodulin, DJ-1,
Ran, 14-3-3 and b-actin.
doi:10.1371/journal.pone.0081314.g003
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finding is of interest because histone proteins share certain features
with aSyn – small size (aSyn: 140 aminoacids; H3: 136
aminoacids) and high lysine content (aSyn: 15; H3: 13) –
suggesting that enhancement of immunodetection by lysine
modification may be a common theme among small, lysine-rich
proteins.
Discussion
Here, we present a simple method to markedly increase
Western blot signals of aSyn by improving its retention on blot
membranes. Our method involves protein modification by the
cleavable amine-reactive crosslinker DSP followed by reductive
cleavage of the crosslinks. In our optimized protocol, intact cells or
cell lysates (2–5 mg/mL protein concentration) are treated with 2
mM DSP at 37uC for 30 min, followed by addition of 50 mM Tris
(pH 7.6) to quench remaining crosslinker, and then boiling in
dodecyl sulfate sample buffer containing 5% bME. Higher
concentrations of DSP did not further enhance aSyn immunore-
activity. Beneficial effects of bME treatment alone were ruled out.
A recently published method of improving aSyn immunodetec-
tion, i.e., incubation of blot membranes in 0.4% PFA [12], is less
effective than our DSP-based method, and treatment with PFA in
addition to DSP did not improve immunodetection beyond the
effect of DSP/bME alone.
The study describing the PFA method begins with the
observation that endogenous aSyn in neuroblastoma cells is easily
detected by fluorescent immunocytochemistry but not by standard
Western blotting, despite the generally higher sensitivity of the
latter technique [12]. Noting a previously reported method using
the fixative PFA to improve immunodetection of hemoglobin, the
authors applied this to Western blots of aSyn and found that the
discrepancy between immunocytochemistry and WB was resolved
[13]. Regarding the mechanism of the effect, they showed that the
PFA method reduced aSyn wash-off from blot membranes. In our
recent aSyn study [7], we observed discrepancies between aSyn
immunodetection in crosslinked and non-crosslinked samples:
aSyn immunodetection was greatly reduced in non-crosslinked
samples [7]. With the PFA method, we could partially overcome
Figure 4. DSP/bME treatment facilitates easy detection of aSyn from cultured cells. A. Cytosols (post-100,000 g) of 3D5 aSyn tet-off cells in
induced (3D5I) or repressed state (3D5R) as well as lysates of the parental neuroblastoma cell line M17D were crosslinked with 2 mM DSP, followed by
boiling in sample buffer with 5% bME. Western blot analysis was performed for aSyn (C20), DJ-1 and b-actin. (Note that the DJ-1 blot shows residual
C20 signal from a previous exposure.) B. Cytosols (post-100,000 g) of neuroblastoma cell lines M17D and SH-SY5Y as well as the PBS-soluble fraction
of human brain homogenates were incubated in 2 mM DSP, followed by boiling in sample buffer with 5% bME and blotting for aSyn (2F12) as well as
b-tubulin. A long and a short exposure of the 2F12 blot are shown. C. Cytosols (post-100,000 g) of SH-SY5Y cells were crosslinked with 2 mM DSP,
followed by boiling in sample buffer/5% bME and blotting for the indicated antibodies. Membranes were cut at dotted lines after protein transfer and
the left half was incubated in 0.4% PFA for 30 min, while the right half was blocked immediately. Membranes were reassembled before film
development; PFA-treated and -untreated halves shown were exposed identically. D. M17D cells analyzed analogously to SH-SY5Y cells in Fig. 4c. In
addition to aSyn and UCH-L1, histone protein H3 was detected using a total H3 as well as an H3 lysine 27-methylation-specific antibody (H3 K27met).
doi:10.1371/journal.pone.0081314.g004
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crosslinker modification and that the crosslinker, similarly to PFA,
improved retention of aSyn on Western blots. However, even with
PFA treatment of blot membranes, we found that untreated or
lightly crosslinked samples routinely yielded lower aSyn monomer
immunodetection than more highly crosslinked samples (see Fig.
1). This indicated that crosslinker modification improved retention
of aSyn to a greater extent than the PFA method, even when the
crosslinker is cleaved to yield just monomers. Indeed, DSP/bME
treatment generally led to stronger aSyn signals relative to PFA
treatment alone, while the PFA method was always superior to
completely untreated samples (e.g., Fig. 4c and 4d). Nearly
complete retention on membranes of recombinant aSyn treated
with DSP/bME after hours of washing, in contrast to the
substantial loss of untreated protein, confirms that the DSP/
bME method, like PFA treatment, effects stronger immunodetec-
tion by enhancing retention on the blot membrane rather than
through epitope accessibility. Moreover, the close to complete
retention observed suggests that further enhancement of aSyn
immunodetection may not be necessary.
The mechanism underlying the reported PFA effect is not self-
evident [13]. The chemical inertness of PVDF and nitrocellulose
makes formation of covalent bonds with aSyn, by reaction with
PFA, improbable. As proteins bind to blot membranes through
non-covalent, primarily hydrophobic interactions [21,22], small
hydrophilic proteins like aSyn are not expected to bind as strongly
as larger, more hydrophobic proteins. It is thus possible that PFA
exerts its stabilizing effect on aSyn through formation of covalent
bonds with other proteins that adhere more firmly to the blot
membrane. However, Lee and Kamitani showed that the PFA
method is effective even with purified aSyn. We similarly show
that purified aSyn is retained on membranes to a greater extent
with DSP/bME treatment than without, indicating that modifi-
cation of lysine residues is sufficient for retention (Fig. 2d). Another
amine-reactive, reducible crosslinker, DTBP, also enhanced aSyn
immunoblotting though not as greatly as DSP; this difference may
be due to the positive charge of the amidine product of the DTBP-
lysine reaction instead of the uncharged amide product of the
DSP-lysine reaction. Furthermore, the strong effect of DSP/bME
treatment, despite cleavage of the crosslinker, makes intermolec-
ular crosslinking of aSyn an unlikely explanation for the PFA
effect.
We hypothesize that both PFA and DSP/bME effects occur
through a combination of: a) masking the positive charges of
lysines (of which aSyn has 15), thereby increasing aSyn
hydrophobicity and blot membrane binding; and b) adding to
aSyn a net hydrophobic moiety large enough to confer stronger
interaction with the blot membrane. As non-immunological stains
- Coomassie Blue dye - also show that crosslinker-modified aSyn
can be fully retained on membranes, unlike unmodified aSyn (Fig.
2d), the enhanced immunodetection is probably not mediated by
improved epitope accessibility. The closely similar results with all
aSyn (as well as b- and cSyn) antibodies we tested further
corroborate this conclusion. It was surprising that, with some
exceptions such as GAPDH, modification of lysines did not
negatively interfere with immunodetection of most proteins tested.
The DSP/bME effect was even observed for the Syn1 antibody,
whose recognized epitope contains lysines. Based on our
experience with aSyn, we postulated that other small, lysine-rich
proteins like the aSyn homologs bSyn and cSyn and histone-
family proteins might similarly benefit from DSP/bME treatment.
Indeed, we observed enhanced Western blot detection upon DSP/
bME treatment for all three synucleins and the histone H3 (other
histones not tested) (Figs. 2b and 4d).
Our results support a conclusion from the Lee and Kamitani
paper, that the field must reconsider the notion that immortalized
cell lines are necessarily very low in aSyn expression. Our data
show that they indeed have lower expression levels than brain
homogenates, but aSyn is believed to constitute up to 1% of
cytosolic proteins in neural tissue [23], and thus, the relatively
lower levels detected by our method for the neuroblastoma cell
lines M17D and SH-SY5Y may still be relatively high compared
to other cellular proteins. Therefore, we propose using our new
method in future studies of aSyn using Western blotting, at least in
comparison to traditional Western blot protocols or the PFA-alone
method, especially when analyzing sources with low levels or rare
forms of aSyn such as secreted aSyn, low abundance splice
variants, or possibly rare modifications of aSyn. Similarly, our
method ensures detection of nearly all aSyn present at 14 kDa
after transfer, allowing more quantitatively correct study of, for
example, the relative abundance of high molecular weight
aggregates and unaggregated oligomers by Western blotting (as
shown and discussed for the PFA method in [12]). Finally, we
propose DSP/bME treated samples to be the correct control to
estimate total aSyn levels in comparison to the different oligomeric
species trapped by uncleaved crosslinkers when performing
crosslinking analyses of physiological aSyn oligomerization. If
one used a vehicle-only control instead of DSP/bME, the
consequent loss of aSyn monomer would give the impression that
the crosslinked sample contained additional aSyn that was
generated by the crosslinking. It should be remembered, however,
that treatment with DSP/bME or PFA may mask antibody
epitopes, although we did not observe such an effect with any of
our aSyn, bSyn, cSyn or histone antibodies, nor for most of our
control antibodies. However, each antibody needs to be assessed
independently, regardless of its target. An additional caveat of our
method is that certain standard biochemical analyses of protein
lysates treated with DSP/bME may be altered, such as assays to
determine protein concentrations or Ponceau membrane staining,
in which masking of lysines interferes with binding of the dye to
proteins. To overcome these limitations, we suggest normalizing
samples before DSP treatment and visualizing proteins on blot
membranes by methods less dependent on the presence of positive
charges.
In conclusion, the present method should be useful for all
synuclein researchers who want to study, by Western blotting, the
total synuclein in a given cellular, tissue or in vitro sample rather
than just the small fraction detected using standard techniques.
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